Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Is MRD monitoring prior to allograft standard in AML?

Michael Heuser, MD, Hannover Medical School, Hannover, Germany, talks on standard practice and measurable residual disease (MRD) monitoring prior to allograft in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.